Cancer Therapeutics announces validation and performance of CTx-294886 plus Avastin

[News]

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin (bevacizumab - Genentech/Roche) in a preclinical model of breast cancer.

More... (http://www.news-medical.net/news/20120705/Cancer-Therapeutics-announces-validation-and-performance-of-CTx-294886-plus-Avastin.aspx)